# US Porcine Vaccines Market

> US Porcine Vaccines Market Research Report By Type (Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines), By Disease Indication (PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD), Others) and By End-user (Veterinary Hospitals, Hog Production Farm) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.27%
- **2024:** $ 230.4 Million
- **2025:** $ 242.54 Million
- **2035:** $ 405.4 Million
- **Key Players:** Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR)

**Report ID:** MRFR/Pharma/17959-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-porcine-vaccines-market-19506

---

## Market Summary

## **US Porcine Vaccines Market Overview**

As per MRFR analysis, the US Porcine Vaccines Market Size was estimated at 375.9 (USD Million) in 2023. The US Porcine Vaccines Market Industry is expected to grow from 403.2(USD Million) in 2024 to 786.4 (USD Million) by 2035. The US Porcine Vaccines Market CAGR (growth rate) is expected to be around 6.261% during the forecast period (2025 - 2035).

### **Key US Porcine Vaccines Market Trends Highlighted**

The US Porcine Vaccines Market has been witnessing significant trends driven by various factors. One of the key market drivers in this region is the rising concern over livestock health and the increasing incidence of diseases among pigs. As a result, hog producers are increasingly investing in vaccination programs to enhance herd immunity and productivity. This trend is amplified by regulatory frameworks and guidelines that mandate vaccinations to maintain animal welfare standards, thus pushing producers to adopt vaccine solutions more actively. Opportunities in the US market include the development of innovative vaccines that target specific pathogens affecting swine.

There is a strong demand for vaccines that provide broader protection against multiple diseases, as swine health directly influences the agricultural economy. With the ongoing advancements in biotechnology, the creation of genetically engineered vaccines is a prospect that can be tapped into. Additionally, collaborations between vaccine manufacturers and academic research institutions can facilitate the discovery of new vaccine candidates that address emerging viral threats. Recent trends also indicate a growing acceptance of the use of animal health products by farmers and producers focused on sustainable practices.

There is an increasing preference for vaccines that are safe, effective, and environmentally friendly, aligning with consumer demand for ethically produced pork.

This shift towards sustainability reflects a more extensive movement towards responsible farming. Moreover, online platforms and e-commerce are emerging as popular channels for purchasing porcine vaccines, enabling easier access for producers across the US. Overall, the US Porcine Vaccines Market is evolving rapidly, responding to the needs of the livestock industry while maintaining a focus on animal health and sustainability.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **US Porcine Vaccines Market Drivers**

#### **Increasing Instances of Swine Diseases**

The US [Porcine Vaccines Market](../../../reports/porcine-vaccines-market-7438) Industry is driven significantly by the rising instances of swine diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS) and Porcine Epidemic Diarrhea (PED). These diseases have considerable direct economic impacts, leading to a loss of billions in the swine industry. Recent data from the United States Department of Agriculture (USDA) indicates that approximately 60% of swine herds are affected by PRRS in the US, leading to significant mortality and productivity loss.

This has prompted farmers to increasingly adopt vaccination protocols to safeguard their herds. Major organizations like the American Association of Swine Veterinarians are actively promoting vaccination as a crucial measure for disease prevention, further bolstering market growth in this sector. As farmers seek to enhance herd immunity and ensure animal welfare, the demand for effective porcine vaccines is anticipated to grow consistently.

#### **Technological Advancements in Vaccine Development**

The development of advanced vaccine technologies is another driver fueling the growth of the US Porcine Vaccines Market Industry. Innovations, such as DNA and recombinant vaccines, are becoming increasingly popular. According to the Centers for Disease Control and Prevention (CDC), these technologies improve the efficacy and safety of vaccines, which contributes to higher adoption rates. Companies like Zoetis and Merck Animal Health are leading in Research and Development (R&D) efforts for new vaccine formulations, making significant investments to ensure their products meet the evolving needs of swine health.

The continuous advancements in vaccine effectiveness directly influence the willingness of farmers to invest in these solutions, propelling market expansion.

#### **Government Support for Animal Health Programs**

Government initiatives aimed at enhancing the health of livestock are pivotal in driving the US Porcine Vaccines Market Industry. The USDA has established various programs to educate farmers about the importance of vaccination and disease prevention. Additionally, funding for veterinary services and vaccination campaigns has seen a notable increase, with appropriations from the USDA for veterinary services reaching hundreds of millions of dollars annually.

This financial support plays a critical role in ensuring that farmers can access necessary vaccinations without financial strain, thereby encouraging more widespread adoption of vaccine protocols to protect their herds. Such initiatives reflect a long-term commitment to animal health and consequently drive growth in porcine vaccines.

### **US Porcine Vaccines Market Segment Insights**

#### **Porcine Vaccines Market Type Insights**

The US Porcine Vaccines Market is segmented by Type into several categories that play a crucial role in maintaining the health and productivity of swine. Vaccination is a significant practice within the porcine industry, aimed at controlling various infectious diseases that can impact swine, leading to economic losses for farmers and producers. Inactivated vaccines are notable for their established efficacy in providing immunity against specific pathogens, making them a cornerstone in swine disease management strategies. These vaccines have proved to be safe and effective, leading to their widespread adoption among veterinarians and swine producers.

Live attenuated vaccines hold substantial importance too, as they often elicit a strong immune response after limited doses, thus enhancing efficiency in disease control and prevention.

Further, toxoid vaccines are essential in the prevention of diseases caused by toxins produced by certain bacteria. Their role is pivotal in protecting swine from diseases that could otherwise lead to serious health issues, highlighting the significance of maintaining herd immunity within the US porciculture sector. Recombinant vaccines are gaining traction owing to their ability to deliver enhanced immune responses and specificity, while also reducing the risk of adverse reactions, making them valuable in contemporary swine health management programs.

Conjugate vaccines also add another layer of sophistication to swine immunization, with their ability to generate responses against polysaccharide capsules of pathogens, thus broadening the protective coverage against multiple strains.

Moreover, DNA vaccines represent an innovative advance in vaccine technology, offering the potential for rapid development and improved stability. Their growing interest in the market stems from their ability to provide long-lasting immunity and protection against emerging swine diseases. Overall, these categories within the US Porcine Vaccines Market showcase a dynamic landscape where each type of vaccine contributes uniquely to herd health and overall productivity of the swine industry. The steady demand for advanced vaccine solutions in the face of evolving diseases further exemplifies the importance of ongoing Research and Development efforts.

The market's growth is underscored by the need for effective disease control measures, driving the use of diverse vaccine types while also addressing challenges such as antibiotic resistance and the rising costs of swine production.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### **Porcine Vaccines Market Disease Indication Insights**

The Disease Indication segment within the US Porcine Vaccines Market plays a vital role in safeguarding the health of swine populations, crucial for both animal welfare and economic stability. This segment encompasses several significant diseases that affect pigs, including Porcine Epidemic Diarrhea (PED), which has been particularly impactful in the market due to its high morbidity and mortality rates in young piglets. Moreover, Porcine Reproductive and Respiratory Syndrome (PRRS) is another dominant factor, leading to substantial production losses and increased veterinary care costs.

Swine influenza, Aujeszky's disease, and Porcine Circovirus Associated Disease (PCVAD) also significantly contribute to production inefficiencies and economic burdens for producers. The prevalence of these diseases in the US highlights the increasing demand for effective vaccines, as farmers and veterinary professionals aim to mitigate outbreaks, improve herd health, and maintain food supply chains. With an ongoing focus on developing targeted and enhanced vaccine solutions, the market remains responsive to emerging threats, aiming to fortify the swine industry in the face of evolving disease challenges.

As a result, the overall US Porcine Vaccines Market segmentation reflects a strategic endeavor to address critical health issues within the swine population and foster sustainable agriculture.

#### **Porcine Vaccines Market End-user Insights**

The End-user segment of the US Porcine Vaccines Market comprises essential entities like Veterinary Hospitals and Hog Production Farms, both pivotal in shaping the market landscape. Veterinary Hospitals play a crucial role in administering vaccines and providing essential health care services to swine. They ensure that swine are protected against various infectious diseases, thereby maintaining herd health and productivity. Within the hog production sector, Hog Production Farms are significant players as they adopt advanced vaccination protocols to safeguard their livestock from disease outbreaks.

This not only enhances the income potential for farmers but also ensures food safety for consumers. The growing emphasis on biosecurity and preventive healthcare in the U.S. agriculture sector further underscores the importance of these End-users in the US Porcine Vaccines Market. In addition, the increasing demand for pork products has driven production farms to seek effective vaccination strategies, making them pivotal for the market's development. Overall, this segment's proficiency in disease management is vital for sustaining the health of the swine population and addressing emerging challenges such as antibiotic resistance.

### **US Porcine Vaccines Market Key Players and Competitive Insights**

The US Porcine Vaccines Market is a sector characterized by rapid growth and innovation, driven by a rising demand for healthier and more productive livestock. This market is witnessing an increase in research and development efforts to introduce advanced immunizations, addressing diseases specific to swine. The competitive landscape is marked by a few dominant players who are leveraging technological advancements and developing unique formulations to cater to the evolving needs of pig producers.

Regulatory approvals and cost-effective production methods have become pivotal factors for success, as companies strive to enhance their market share and establish deeper connections with veterinarians and farmers. As the animal health industry increasingly prioritizes preventive measures, understanding the competitive dynamics within this market is essential for stakeholders aiming for sustainability and profitability.

#### Vetoquinol

Vetoquinol is a well-established entity within the US Porcine Vaccines Market, known for its strong commitment to research and development, which helps in creating effective vaccine solutions specifically for swine diseases. The company has cultivated a solid reputation based on its expertise in veterinary medicines and its ability to adapt to changing market demands. Vetoquinol's dedicated approach in fostering relationships with veterinarians and livestock producers further enhances its market presence, as these partnerships often result in product endorsements and raised awareness of its vaccines.

Vetoquinol is particularly recognized for its efficacy and quality, which has translated into a loyal customer base that values the reliability of its vaccine offerings. Their strategic initiatives in distributing high-quality products and providing comprehensive support enhance their competitive stance in the market.

#### Kemin Industries

Kemin Industries plays a significant role in the US Porcine Vaccines Market, emphasizing the production and distribution of a range of health and nutrition products for livestock. The company’s offerings include innovative vaccine solutions alongside nutritional supplements targeted at enhancing pig health and productivity. Kemin Industries has made its mark by investing in research and development to create effective swine vaccines while also ensuring compliance with regulatory standards. Their strong market presence is bolstered by strategic collaborations, partnerships, and potential acquisitions that expand their portfolio and reach across the US.

The company’s infrastructure and distribution channels enable them to effectively deliver their products, while a focus on networking with livestock producers and veterinarians has established their reputation as an industry leader. Kemin Industries continuously strives to optimize swine health through their comprehensive approach, combining vaccines with nutritional and health solutions.

#### Key Companies in the US Porcine Vaccines Market Include

- Vetoquinol
- Kemin Industries
- IDT Biologika
- Neogen Corporation
- Zoetis
- **[Merck Animal Health](https://www.merck-animal-health.com/products/swine/)**
- Elanco Animal Health
- Boehringer Ingelheim
- HIPRA
- Lallemand Animal Nutrition
- Phibro Animal Health
- Valley Vet Supply
- Intervet
- Ceva Santé Animale
- Cloudburst Animal Health

### **US Porcine Vaccines Market Industry Developments**

The US Porcine Vaccines Market has recently seen significant developments, particularly with advancements in vaccine efficacy and safety. Companies like Zoetis and Merck Animal Health have been at the forefront, introducing innovative vaccines aimed at enhancing swine health and productivity. In addition, Kemin Industries has launched products that address emerging health challenges in swine, focusing on providing effective solutions against viral infections. Notably, in February 2023, Boehringer Ingelheim announced the acquisition of a biotechnology firm specializing in pig vaccines, strengthening its portfolio in animal health. Kemin Industries also acquired a prominent competitor in March 2023, further solidifying its market position.

Over the past two to three years, there has been a notable increase in market valuation, driven by demands for improved animal welfare and biosecurity measures, aligning with USDA initiatives. The rise in government support for pork producers has bolstered the need for effective vaccines, resulting in a surge in Research and Development activities within major companies such as Elanco Animal Health and Neogen Corporation, aimed at addressing current and future health threats in porcine populations.

### **US Porcine Vaccines Market Segmentation Insights**

#### **Porcine Vaccines Market Type Outlook**

- Inactivated vaccines
- Live attenuated vaccines
- Toxoid vaccines
- Recombinant vaccines
- Conjugate vaccines
- DNA vaccines

#### **Porcine Vaccines Market Disease Indication Outlook**

- PED (Porcine Epidemic Diarrhea)
- PRRS (Porcine Reproductive & Respiratory Syndrome)
- Swine influenza
- Aujeszky's disease (AD)
- Porcine Circovirus Associated Disease (PCVAD)
- Others

#### **Porcine Vaccines Market End-user Outlook**

- Veterinary Hospitals
- Hog Production Farm

## Market Drivers

### Emerging Infectious Diseases

The emergence of new infectious diseases affecting swine populations is a significant concern for the porcine vaccines market. Diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS) and African Swine Fever (ASF) pose substantial threats to herd health and productivity. The USDA has reported increased incidences of these diseases, prompting a heightened need for effective vaccination solutions. As producers face potential economic losses due to disease outbreaks, the demand for innovative vaccines is expected to rise. This urgency to protect livestock health and ensure biosecurity measures will likely drive growth in the porcine vaccines market, as stakeholders prioritize disease prevention strategies.

### Rising Demand for Pork Products

The increasing consumption of pork in the United States is a primary driver for the porcine vaccines market. As pork remains a staple protein source, the demand for healthy livestock is paramount. According to the USDA, pork production is projected to reach approximately 27 million metric tons by 2025. This surge in production necessitates effective vaccination strategies to prevent disease outbreaks, thereby ensuring a stable supply chain. The porcine vaccines market is likely to benefit from this trend, as producers seek to enhance herd immunity and reduce mortality rates. Consequently, the focus on maintaining high-quality pork products drives investments in vaccine development and distribution, further propelling the market forward.

### Advancements in Vaccine Technology

Technological innovations in vaccine development are transforming the porcine vaccines market. The introduction of novel vaccine platforms, such as mRNA vaccines and vector-based vaccines, offers enhanced efficacy and safety profiles. These advancements allow for quicker responses to emerging diseases and improved herd immunity. The market is witnessing a shift towards more effective vaccination strategies, which could potentially reduce the incidence of disease outbreaks. Furthermore, the USDA supports research initiatives aimed at developing next-generation vaccines, indicating a commitment to advancing animal health. As these technologies become more widely adopted, they are likely to reshape the landscape of the porcine vaccines market.

### Increased Investment in Animal Health

The growing recognition of animal health's impact on food security is driving investment in the porcine vaccines market. Stakeholders, including government agencies and private companies, are allocating resources to enhance vaccine research and development. The USDA has noted a rise in funding for animal health initiatives, which is expected to foster innovation in vaccine formulations and delivery methods. This influx of capital may lead to the introduction of more effective vaccines, addressing the evolving challenges faced by swine producers. As the industry prioritizes animal welfare and productivity, the porcine vaccines market is likely to experience robust growth fueled by these investments.

### Regulatory Support for Vaccine Development

Regulatory frameworks in the United States are increasingly supportive of vaccine development, which is a crucial driver for the porcine vaccines market. The USDA and FDA have established guidelines that facilitate the approval process for new vaccines, ensuring that they meet safety and efficacy standards. This regulatory environment encourages pharmaceutical companies to invest in research and development, leading to a more diverse range of vaccine options for swine producers. As the market expands, compliance with these regulations will be essential for maintaining consumer trust and ensuring the health of livestock. Consequently, the supportive regulatory landscape is likely to bolster the growth of the porcine vaccines market.

## Future Outlook

The [Porcine Vaccines Market](https://www.marketresearchfuture.com/reports/porcine-vaccines-market-7438) is projected to grow at a 5.27% CAGR from 2025 to 2035, driven by increasing disease outbreaks, advancements in vaccine technology, and rising demand for pork products.

**New opportunities:**

- Development of customized vaccine formulations for specific regional diseases. Expansion of e-commerce platforms for vaccine distribution. Investment in research for novel adjuvants to enhance vaccine efficacy.

By 2035, the porcine vaccines market is expected to achieve robust growth and innovation.

## Segment Insights

### By Type: Inactivated Vaccines (Largest) vs. Live Attenuated Vaccines (Fastest-Growing)

In the US porcine vaccines market, the distribution of market share among different vaccine types reveals that inactivated vaccines account for a significant portion, representing the largest segment. Live attenuated vaccines follow closely behind, showing promise due to their effectiveness and rapid adoption in the field. Toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines contribute to the overall market but hold smaller shares compared to their inactivated and live counterparts.

The growth trends within this segment are predominantly driven by increased awareness of animal health and advancements in vaccine technologies. The demand for innovative solutions that ensure the welfare of swine herds is propelling live attenuated vaccines into the spotlight, establishing them as the fastest-growing segment. Toxoid and recombinant vaccines also exhibit potential as producers look for alternative methods to enhance immunity in pigs during circovirus outbreaks and other diseases.

Inactivated Vaccines (Dominant) vs. Live Attenuated Vaccines (Emerging)

Inactivated vaccines are recognized as the dominant choice in the US porcine vaccines market, primarily due to their established efficacy, safety profiles, and regulatory approvals. These vaccines induce robust immune responses, making them crucial in preventing various infectious diseases in swine populations. Conversely, live attenuated vaccines emerge as a leading alternative, representing a growing segment that appeals to producers seeking effective, long-lasting immunity. Their capability to stimulate a natural immune response and the trend towards preventive health measures in livestock are driving their increasing adoption. As producers prioritize animal health and productivity, the emergence of live attenuated vaccines continues to reshape the competitive landscape.

### By Disease Indication: PRRS (Largest) vs. PED (Fastest-Growing)

In the US porcine vaccines market, the market share distribution among various disease indications reveals that Porcine Reproductive & Respiratory Syndrome (PRRS) holds the largest share, attributed to its significant impact on the swine industry. Following PRRS, Porcine Epidemic Diarrhea (PED) has established a notable position as a critical concern for producers, especially during outbreaks. Other indications, such as swine influenza and Aujeszky's disease, contribute to the overall portfolio but have comparatively lower shares.

Growth trends in the US porcine vaccines market are substantially influenced by increasing industrialization in swine farming and heightened awareness among producers regarding disease prevention. The demand for effective vaccines against emerging diseases, particularly PED, is accelerating. Technological advancements in vaccine development are supporting rapid market growth, aiming to address the urgent needs driven by the rising incidence of swine diseases among herds.

Disease Indications: PRRS (Dominant) vs. PED (Emerging)

In the US porcine vaccines market, Porcine Reproductive & Respiratory Syndrome (PRRS) is recognized as the dominant disease indication, largely because it poses substantial economic threats to swine herds. Its prevalence necessitates consistent vaccination strategies, strengthening its market position. In contrast, Porcine Epidemic Diarrhea (PED) is emerging rapidly, especially due to its capability to cause severe gastrointestinal disturbances in pigs. The urgency to combat PED is reflected in increased research funding and development efforts. Both segments indicate the shifting dynamics of disease management in the swine industry, with PRRS continuing to lead while PED gains traction as a critical area of focus.

### By End-user: Hog Production Farm (Largest) vs. Veterinary Hospitals (Fastest-Growing)

In the US porcine vaccines market, the distribution of market share among different end-user segments reveals that Hog Production Farms hold the largest share, benefitting from direct demand driven by the scale of hog farming operations. Veterinary Hospitals, while currently smaller in market share, are witnessing rapid adoption of advanced vaccination practices, making them a crucial player in the market landscape.

Growth trends are favoring Veterinary Hospitals as they expand their service offerings and capabilities in swine health management. The increasing awareness of animal health and welfare, alongside emerging technologies in vaccine development, boosts their relevance. Meanwhile, Hog Production Farms are seeing sustained growth due to rising consumption of pork and the need for enhanced biosecurity measures, ensuring both segments are pivotal to market dynamics.

Veterinary Hospitals (Emerging) vs. Hog Production Farm (Dominant)

Hog Production Farms dominate the US porcine vaccines market due to their vast scale and integration of vaccination into routine herd health management. These farms prioritize efficacy and biosecurity in vaccine selection, translating into substantial demand for effective vaccination solutions. Conversely, Veterinary Hospitals represent an emerging segment, characterized by their increasing role in swine health. They are evolving from traditional practices to more advanced veterinary care, adopting new vaccine technologies and protocols to enhance animal health outcomes. This expansion is driven by an increasing number of veterinary practitioners specializing in swine, reflecting a broader trend toward enhanced animal welfare standards and the professionalization of veterinary services in the sector.

## Competitive Benchmarking

The porcine vaccines market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansions. Key players such as Zoetis (US), Merck Animal Health (US), and Boehringer Ingelheim (DE) are at the forefront, leveraging their extensive research capabilities and market presence to drive growth. Zoetis (US) focuses on developing advanced vaccine formulations that enhance efficacy and safety, while Merck Animal Health (US) emphasizes strategic collaborations to broaden its product portfolio. Boehringer Ingelheim (DE) appears to be investing heavily in digital transformation initiatives, aiming to streamline operations and improve customer engagement. Collectively, these strategies contribute to a dynamic competitive environment, where innovation and operational efficiency are paramount.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain resilience. The market structure is moderately fragmented, with several players vying for market share, yet a few dominant firms hold significant influence. This competitive structure allows for a diverse range of products and services, catering to various customer needs while fostering an environment ripe for innovation.
In October Zoetis (US) announced the launch of a new vaccine targeting Porcine Reproductive and Respiratory Syndrome (PRRS), a significant advancement in the fight against this prevalent disease. This strategic move not only reinforces Zoetis's commitment to addressing critical health challenges in swine production but also positions the company to capture a larger market share in the growing demand for effective vaccines. The introduction of this vaccine is expected to enhance herd immunity and reduce economic losses for producers.
In September Merck Animal Health (US) entered into a partnership with a leading agricultural technology firm to integrate AI-driven analytics into its vaccine development processes. This collaboration aims to optimize vaccine efficacy and streamline production timelines. By harnessing AI, Merck is likely to enhance its research capabilities, potentially leading to faster and more effective vaccine solutions that meet the evolving needs of the market.
In August Boehringer Ingelheim (DE) expanded its manufacturing facility in the US, a strategic decision aimed at increasing production capacity for its porcine vaccines. This expansion not only reflects the company's commitment to meeting rising demand but also underscores its focus on maintaining high-quality standards in vaccine production. The increased capacity is expected to bolster Boehringer Ingelheim's competitive position in the market, allowing for quicker response times to customer needs.
As of November the competitive trends in the porcine vaccines market are increasingly defined by digitalization, sustainability, and the integration of advanced technologies such as AI. Strategic alliances are becoming more prevalent, enabling companies to pool resources and expertise to drive innovation. Looking ahead, it is anticipated that competitive differentiation will evolve, shifting from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This transition may ultimately enhance the overall resilience and sustainability of the market.

## Recent News & Developments

The US Porcine Vaccines Market has recently seen significant developments, particularly with advancements in vaccine efficacy and safety. Companies like Zoetis and Merck Animal Health have been at the forefront, introducing innovative vaccines aimed at enhancing swine health and productivity. In addition, Kemin Industries has launched products that address emerging health challenges in swine, focusing on providing effective solutions against viral infections. Notably, in February 2023, Boehringer Ingelheim announced the acquisition of a biotechnology firm specializing in pig vaccines, strengthening its portfolio in animal health. Kemin Industries also acquired a prominent competitor in March 2023, further solidifying its market position.

Over the past two to three years, there has been a notable increase in market valuation, driven by demands for improved animal welfare and biosecurity measures, aligning with USDA initiatives. The rise in government support for pork producers has bolstered the need for effective vaccines, resulting in a surge in Research and Development activities within major companies such as Elanco Animal Health and Neogen Corporation, aimed at addressing current and future health threats in porcine populations.

## Report Scope

| MARKET SIZE 2024 | 230.4(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 242.54(USD Million) |
| MARKET SIZE 2035 | 405.4(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.27% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR) |
| Segments Covered | Type, Disease Indication, End-user |
| Key Market Opportunities | Advancements in vaccine technology enhance disease prevention in the porcine vaccines market. |
| Key Market Dynamics | Rising demand for innovative porcine vaccines driven by regulatory changes and technological advancements in animal health. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US porcine vaccines market in 2024?**
A: The market valuation of the US porcine vaccines market was $230.4 Million in 2024.

**Q: What is the projected market valuation for the US porcine vaccines market by 2035?**
A: The projected market valuation for the US porcine vaccines market is $405.4 Million by 2035.

**Q: What is the expected CAGR for the US porcine vaccines market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US porcine vaccines market during the forecast period 2025 - 2035 is 5.27%.

**Q: Which companies are considered key players in the US porcine vaccines market?**
A: Key players in the US porcine vaccines market include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, Ceva Santé Animale, Virbac, Heska Corporation, and Vetoquinol.

**Q: What are the main types of vaccines in the US porcine vaccines market?**
A: The main types of vaccines in the US porcine vaccines market include inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines.

**Q: What was the valuation range for live attenuated vaccines in 2024?**
A: The valuation range for live attenuated vaccines in 2024 was between $60.0 Million and $100.0 Million.

**Q: Which disease indications are covered by the US porcine vaccines market?**
A: Disease indications covered by the US porcine vaccines market include Porcine Epidemic Diarrhea (PED), Porcine Reproductive & Respiratory Syndrome (PRRS), swine influenza, Aujeszky's disease, and Porcine Circovirus Associated Disease (PCVAD).

**Q: What is the projected valuation for the hog production farm segment by 2035?**
A: The projected valuation for the hog production farm segment is expected to reach $265.4 Million by 2035.

**Q: What was the valuation for the veterinary hospitals segment in 2024?**
A: The valuation for the veterinary hospitals segment was $80.0 Million in 2024.

**Q: How does the market for recombinant vaccines compare to other types in terms of valuation?**
A: The valuation for recombinant vaccines ranges from $50.0 Million to $80.0 Million, indicating a competitive position among other vaccine types.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-porcine-vaccines-market-19506*